Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies

Clinical trials with SRC family kinases (SFKs) inhibitors used alone or in a combination with anti-CD20 monoclonal antibodies (mAbs) are currently underway in the treatment of B-cell tumors. However, molecular interactions between these therapeutics have not been studied so far. A transcriptional pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Winiarska, Magdalena, Bojarczuk, Kamil, Pyrzynska, Beata, Bil, Jacek, Siernicka, Marta, Dwojak, Michal, Bobrowicz, Malgorzata, Miazek, Nina, Zapala, Piotr, Zagozdzon, Agnieszka, Krol, Magdalena, Syta, Aleksandra, Podszywalow-Bartnicka, Paulina, Pilch, Zofia, Dabrowska-Iwanicka, Anna, Juszczynski, Przemyslaw, Efremov, Dimitar G, Slabicki, Mikolaj, Zenz, Thorsten, Roy, Aude Le, Olive, Daniel, Rygiel, Tomasz P, Leusen, Jeanette HW, Golab, Jakub
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622538/
https://www.ncbi.nlm.nih.gov/pubmed/25517315
http://dx.doi.org/10.4161/mabs.32106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622538/
https://www.ncbi.nlm.nih.gov/pubmed/25517315
http://dx.doi.org/10.4161/mabs.32106

Ejemplares similares